middle.news
Neurizon Raises A$24.2m to Propel ALS Drug NUZ-001 into Pivotal Trial
9:59am on Tuesday 23rd of December, 2025 AEDT
•
Healthcare
Read Story
Neurizon Raises A$24.2m to Propel ALS Drug NUZ-001 into Pivotal Trial
9:59am on Tuesday 23rd of December, 2025 AEDT
Key Points
Equity raise of up to A$24.2 million via placement and entitlement offer at A$0.08 per share
Funds to support HEALEY ALS Platform Trial for NUZ-001, a neurodegenerative disease candidate
Global licensing agreement secured with Elanco for manufacturing and regulatory support
Convertible note facility of up to A$20 million arranged with Obsidian Global GP, LLC
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE